$7.13
2.33% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Intellia Therapeutics, Inc. Stock price

$7.30
-2.15 22.75% 1M
-11.25 60.65% 6M
-4.36 37.39% YTD
-17.80 70.92% 1Y
-68.91 90.42% 3Y
-4.60 38.66% 5Y
-14.80 66.97% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.65 9.69%
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Key metrics

Market capitalization $755.67m
Enterprise Value $364.35m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.29
P/S ratio (TTM) P/S ratio 13.06
P/B ratio (TTM) P/B ratio 0.85
Revenue growth (TTM) Revenue growth 59.55%
Revenue (TTM) Revenue $57.88m
EBIT (operating result TTM) EBIT $-534.26m
Free Cash Flow (TTM) Free Cash Flow $-354.66m
Cash position $601.52m
EPS (TTM) EPS $-5.25
P/E forward negative
P/S forward 15.28
EV/Sales forward 7.37
Short interest 29.30%
Show more

Is Intellia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Intellia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Intellia Therapeutics, Inc. forecast:

20x Buy
71%
7x Hold
25%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Intellia Therapeutics, Inc. forecast:

Buy
71%
Hold
25%
Sell
4%

Financial data from Intellia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
58 58
60% 60%
100%
- Direct Costs 10 10
15% 15%
18%
48 48
74% 74%
82%
- Selling and Administrative Expenses 116 116
7% 7%
200%
- Research and Development Expense 456 456
7% 7%
788%
-524 -524
3% 3%
-905%
- Depreciation and Amortization 10 10
15% 15%
18%
EBIT (Operating Income) EBIT -534 -534
4% 4%
-923%
Net Profit -519 -519
8% 8%
-897%

In millions USD.

Don't miss a Thing! We will send you all news about Intellia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Intellia Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
20 minutes ago
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).
Neutral
GlobeNewsWire
about 6 hours ago
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneu...
Neutral
GlobeNewsWire
3 days ago
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).
More Intellia Therapeutics, Inc. News

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO John Leonard
Employees 403
Founded 2014
Website www.intelliatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today